Montelukast%25252525252525252525252525252525252525252525252525252525252525252525252520levocetrizine

# Montelukast levocetirizine ## Overview Montelukast plus levocetirizine is an oral combination of: - **Montelukast:** leukotriene receptor antagonist. - **Levocetirizine:** second-generation H1-antihistamine. Fixed-dose strengths and regulatory approval vary by country. Some products are marketed for allergic rhinitis, but the combination should be dosed according to the individual components and local prescribing information. **Montelukast carries a boxed warning for serious neuropsychiatric effects**, including suicidal thoughts or behavior. For allergic rhinitis, reserve montelukast for patients who have an inadequate response or intolerance to alternatives. ## Primary Indications - **Seasonal or perennial allergic rhinitis** - **Asthma maintenance therapy** with montelukast component; not for acute bronchospasm - Montelukast may also be used for **exercise-induced bronchoconstriction** in appropriate patients Levocetirizine treats allergic symptoms but is not an asthma controller. ## Adult Dosing When administered as separate products: - **Montelukast:** 10 mg orally once daily, usually in the evening. - Maximum: **10 mg/day** - **Levocetirizine:** 5 mg orally once daily, preferably in the evening. - Maximum usual dose: **5 mg/day** Do not exceed the maximum dose of either component by using additional single-agent products. ## Pediatric Dosing ### Montelukast Age-specific doses are indication-dependent but generally: - **6–23 months:** 4 mg once daily for perennial allergic rhinitis; asthma labeling varies by jurisdiction - **2–5 years:** 4 mg once daily - **6–14 years:** 5 mg once daily - **≥15 years:** 10 mg once daily For asthma, administer in the evening. For exercise-induced bronchoconstriction, a single 10-mg dose is used in patients aged ≥15 years; do not repeat within 24 hours. ### Levocetirizine Typical oral dosing: - **6 months–5 years:** 1.25 mg once daily - **6–11 years:** 2.5 mg once daily - **≥12 years:** 5 mg once daily Maximums: - **6 months–5 years:** 1.25 mg/day - **6–11 years:** 2.5 mg/day - **≥12 years:** 5 mg/day A fixed-dose montelukast/levocetirizine product may not provide appropriate pediatric doses. Use separate products when needed. Verify the local product label, particularly for children younger than 2 years. ## Dose Adjustments ### Renal impairment - **Montelukast:** No dosage adjustment is generally required. - **Levocetirizine, adults and adolescents ≥12 years:** - CrCl 50–80 mL/min: **2.5 mg once daily** - CrCl 30–49 mL/min: **2.5 mg every other day** - CrCl 10–29 mL/min: **2.5 mg every 72 hours** - CrCl <10 mL/min or hemodialysis: **contraindicated** Pediatric renal dosing is less well established; consult product-specific guidance or a pediatric specialist. ### Hepatic impairment - **Montelukast:** Usually no adjustment for mild-to-moderate hepatic impairment; data are limited in severe disease. - **Levocetirizine:** No adjustment for isolated hepatic impairment, but reduce dose when renal impairment is present. ### Older adults Use the lowest effective levocetirizine dose, particularly with reduced renal function or risk of sedation/falls. ## Contraindications - Hypersensitivity to montelukast, levocetirizine, cetirizine, hydroxyzine, or any product component - **Levocetirizine:** severe renal impairment or end-stage renal disease requiring dialysis - Use of a fixed-dose combination when its component doses cannot be adjusted safely Montelukast should generally be avoided for mild allergic rhinitis when effective alternatives are tolerated because of neuropsychiatric risk. ## Adverse Effects ### Common - Headache - Abdominal pain, nausea, diarrhea - Fatigue - Somnolence or sedation, especially with levocetirizine - Dry mouth - Upper respiratory symptoms ### Montelukast-specific or clinically important - Neuropsychiatric effects: agitation, aggression, anxiety, depression, insomnia, nightmares, hallucinations, suicidal thoughts or behavior - Eosinophilic granulomatosis with polyangiitis-like illness, rarely associated with systemic corticosteroid reduction - Elevated liver enzymes or hepatitis, rarely - Hypersensitivity reactions, including angioedema ### Levocetirizine-specific - Somnolence, impaired alertness, and fatigue - Urinary retention, particularly in patients with urinary retention risk - Rare hypersensitivity reactions **Stop montelukast and promptly evaluate** new or worsening mood, behavior, sleep, or suicidal symptoms. ## Key Drug Interactions - **Alcohol, opioids, benzodiazepines, sedatives, and other CNS depressants:** increased sedation or impaired alertness with levocetirizine. - **Other antihistamines:** additive sedation and anticholinergic effects; avoid unnecessary duplication. - **Rifampin and other enzyme inducers:** may reduce montelukast exposure; clinical significance is usually limited. - **Gemfibrozil:** increases montelukast exposure; routine adjustment is not generally required, but monitor for adverse effects. - **Theophylline, warfarin, oral contraceptives, and corticosteroids:** no clinically important routine interaction is generally expected with montelukast. - Avoid duplicate therapy with another montelukast-containing or levocetirizine/cetirizine-containing product. ## Monitoring - **Clinical response:** nasal congestion, sneezing, itching, rhinorrhea, nighttime symptoms, and asthma control. - **Neuropsychiatric symptoms:** assess at baseline and after initiation or dose changes; ask caregivers about behavior and sleep in children. - **Sedation and functional impairment:** caution with driving, alcohol, and hazardous activities. - **Renal function:** particularly in older adults, children with renal disease, and anyone receiving levocetirizine chronically. - **Asthma control:** rescue-inhaler use, nighttime awakenings, exacerbations, and lung function when appropriate. - **Hepatic symptoms or laboratory abnormalities** if clinically indicated. ## Clinical Pearls - This combination **does not treat an acute asthma attack**. Patients should have an appropriate rapid-acting rescue inhaler and prescribed controller therapy. - For allergic rhinitis, intranasal corticosteroids are generally more effective than montelukast and are usually preferred first-line therapy. - Take the combination once daily; evening administration is commonly used, but follow the specific product label. - Do not use an extra dose of montelukast before exercise if the patient already takes daily montelukast. - If significant neuropsychiatric symptoms occur, discontinue montelukast and contact the prescriber promptly. - Fixed-dose products may not match renal-adjusted levocetirizine dosing or pediatric dose requirements; separate administration may be safer. - Exact indications, strengths, age limits, and dosing schedules vary by country and product. *Educational information only; verify current local prescribing information, product strength, renal dosing recommendations, and regulatory warnings before prescribing or dispensing.*